A 75-Year-Old Male Develops Painful Erythema Around His Nails After Starting Treatment

Poll

A 75-year-old male patient develops painful erythema around his nails 10 weeks after starting cancer treatment. Which medication is most likely responsible?

A 75-year-old male patient develops painful erythema around his nails 10 weeks after starting cancer treatment. According to the image below, which medication is most likely responsible?

Image courtesy of Shivani V. Tripathi, M.D.  and  Milan J. Anadkat, M.D.

What is your diagnosis?

A. Cyclophosphamide
B. Cetuximab
C. Docetaxel
D. Hydroxyurea
Recent Videos
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
3 experts are featured in this series.
3 experts are featured in this series.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
4 experts are featured in this series.
6 experts are featured in this series.
Related Content
Clonal hematopoiesis may be associated with the early development of toxic events in patients with newly diagnosed multiple myeloma.

CHIP-Carrying Multiple Myeloma Correlates With More Aggressive Disease

Roman Fabbricatore
February 4th 2025
Article

Clonal hematopoiesis may be associated with the early development of toxic events in patients with newly diagnosed multiple myeloma.

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Eric Jonasch, MD
February 3rd 2025
Podcast

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

Support for the recommendation is based on phase 3 ADRIATIC trial results showing a 27% reduction in the risk of death with durvalumab vs placebo.

CHMP Recommends EU Approval for Durvalumab in Limited-Stage SCLC

Roman Fabbricatore
February 4th 2025
Article

Support for the recommendation is based on phase 3 ADRIATIC trial results showing a 27% reduction in the risk of death with durvalumab vs placebo.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

Shwetal Mehta, PhD
January 27th 2025
Podcast

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Integrative Oncology Approaches to Managing Gastrointestinal Cancer

Integrative Oncology Approaches to Managing Gastrointestinal Cancer

Ariana Pelosci
February 4th 2025
Article

Options like acupuncture or cannabis use may be viable to help manage symptoms related to gastrointestinal cancer treatment.

Encorafenib Combo Improves PFS in Metastatic Colorectal Cancer

Encorafenib Combo Improves PFS in Metastatic Colorectal Cancer

Tim Cortese
February 3rd 2025
Article

Full progression-free survival results for patients with BRAF V600E mCRC from the phase 3 BREAKWATER trial will be presented at an upcoming medical conference.